Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
Abstract Background There is no agreed upon standard of care for borderline‐resectable pancreatic cancer (BRPC) or locally‐advanced pancreatic cancer (LAPC) patients regarding the benefit of chemotherapy or radiation alone or in combination. Patients and Methods We completed a retrospective cohort a...
Main Authors: | Gregory P. Botta, Tridu R. Huynh, Samantha R. Spierling‐Bagsic, Alexander Agelidis, Randolph Schaffer, Ray Lin, Darren Sigal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5523 |
Similar Items
-
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01) -
Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series
by: Rachna Gorbudhun, et al.
Published: (2022-09-01) -
Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
by: CHEN Zegang, et al.
Published: (2022-09-01) -
Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
by: Marco Massani, et al.
Published: (2023-01-01) -
Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma
by: Wade Christopher, et al.
Published: (2022-12-01)